Your browser doesn't support javascript.
loading
Shared genetic etiology between idiopathic pulmonary fibrosis and COVID-19 severity
Joao Fadista; Luke M. Kraven; Juha Karjalainen; Shea J. Andrews; Frank Geller; - The COVID-19 Host Genetics Initiative; J Kenneth Baillie; Louise V. Wain; R. Gisli Jenkins; Bjarke Feenstra.
Afiliação
  • Joao Fadista; Statens Serum Institut
  • Luke M. Kraven; University of Leicester
  • Juha Karjalainen; Institute for Molecular Medicine Finland (FIMM)
  • Shea J. Andrews; Icahn School of Medicine at Mount Sinai
  • Frank Geller; Statens Serum Institut
  • - The COVID-19 Host Genetics Initiative; -
  • J Kenneth Baillie; Roslin Institute
  • Louise V. Wain; University of Leicester
  • R. Gisli Jenkins; University of Nottingham
  • Bjarke Feenstra; Statens Serum Institut
Preprint em En | PREPRINT-MEDRXIV | ID: ppmedrxiv-20248279
Artigo de periódico
Um artigo publicado em periódico científico está disponível e provavelmente é baseado neste preprint, por meio do reconhecimento de similaridade realizado por uma máquina. A confirmação humana ainda está pendente.
Ver artigo de periódico
ABSTRACT
BackgroundIdiopathic pulmonary fibrosis (IPF) is a complex lung disease, characterized by progressive lung scarring. Severe COVID-19 is associated with substantial pneumonitis and has a number of shared major risk factors with IPF. This study aimed to determine the genetic correlation between IPF and severe COVID-19 and assess a potential causal role of genetically increased risk of IPF on COVID-19 severity. MethodsWe performed a Mendelian randomisation (MR) study for IPF causality in COVID-19. Genetic variants associated with IPF susceptibility (P<5x10-8) in previous genome-wide association studies (GWAS) were used as instrumental variables (IVs). Effect estimates of those IVs on COVID-19 severity were gathered from the GWAS meta-analysis by the COVID-19 Host Genetics Initiative. The genetic correlation between IPF and COVID-19 severity was estimated with linkage disequilibrium (LD) score regression. FindingsWe detected a positive genetic correlation of IPF with COVID-19 severity (rg=0.31 [95% CI 0.04-0.57], P = 0.023). The MR estimates for severe COVID-19 did not reveal any genetic association (OR 1.05, [95% CI 0.92-1.20], P = 0.43). However, outlier analysis revealed that the IPF risk allele rs35705950 at MUC5B had a different effect compared with the other variants. When rs35705950 was excluded, MR results provided evidence that genetically increased risk of IPF has a causal effect on COVID-19 severity (OR 1.21, [95% CI 1.06-1.38], P = 4.24x10-3). Furthermore, the IPF risk-allele at MUC5B showed an apparent protective effect against COVID-19 hospitalization only in older adults (OR 0.86, [95% CI 0.73-1.00], P = 2.99x10-2). InterpretationThe strongest genetic determinant of IPF, rs35705950 at MUC5B, seems to confer protection against COVID-19, whereas the combined effect of all other IPF risk loci seem to confer risk of COVID-19 severity. The observed effect of rs35705950 could either be due to protective effects of mucin over-production on the airways or a consequence of selection bias due to a patient group that is heavily enriched for the rs35705950 T undertaking strict self-isolation. Due to the diverse impact of IPF causal variants on SARS-CoV-2 infection, further investigation is needed to address this apparent paradox between variance at MUC5B and other IPF genetic risk factors. FundingNovo Nordisk Foundation and Oak Foundation.
Licença
cc_by_nc_nd
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Etiology_studies / Experimental_studies / Prognostic_studies / Review Idioma: En Ano de publicação: 2020 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Etiology_studies / Experimental_studies / Prognostic_studies / Review Idioma: En Ano de publicação: 2020 Tipo de documento: Preprint